44
Participants
Start Date
December 1, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Tirzepatide 2.5mg weekly
"Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen)~Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses."
Placebo injection (normal saline)
Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.
Garvan Institute of Medical Research, Sydney
Lead Sponsor
Garvan Institute of Medical Research
OTHER